Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

HRTX

Heron Therapeutics Inc

Apr 28 • 04:00PM ET

1.21

+0.02 1.68 %

Healthcare • Biotechnology • USA • Micro • NASD

Peers: JNJ PFE ABBV MRK BMY GILD LLY AMGN VRTX REGN

| Held by: VTI IWM VXF IWN SCHA VTWO IWC VHT ITOT PRFZ

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.12	Insider Own	1.59%	Shs Outstand	188.31M	Perf Week	18.63%
Market Cap	228.25M	Forward P/E	10.08	EPS next Y	0.12	Insider Trans	0.00%	Shs Float	185.54M	Perf Month	54.40%
Enterprise Value	323.31M	PEG	-	EPS next Q	-0.02	Inst Own	82.84%	Short Float	22.18%	Perf Quarter	-13.57%
Income	-20.20M	P/S	1.47	EPS this Y	77.78%	Inst Trans	-0.38%	Short Ratio	21.60	Perf Half Y	0.83%
Sales	154.90M	P/B	17.15	EPS next Y	549.99%	ROA	-4.47%	Short Interest	41.15M	Perf YTD	-6.92%
Book/sh	0.07	P/C	4.89	EPS next 5Y	-	ROE	-	52W High	2.61 -53.64%	Perf Year	-48.07%
Cash/sh	0.25	P/FCF	-	EPS past 3/5Y	58.31% 45.44%	ROIC	-13.03%	52W Low	0.74 64.36%	Perf 3Y	-49.37%
Dividend Est.	-	EV/EBITDA	1154.69	Sales past 3/5Y	12.89% 11.81%	Gross Margin	73.31%	Volatility	9.47% 7.26%	Perf 5Y	-93.42%
Dividend TTM	-	EV/Sales	2.09	EPS Y/Y TTM	-30.68%	Oper. Margin	-1.32%	ATR (14)	0.08	Perf 10Y	-94.40%
Dividend Ex-Date	-	Quick Ratio	1.51	Sales Y/Y TTM	7.36%	Profit Margin	-13.04%	RSI (14)	73.29	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	2.48	EPS Q/Q	-165.69%	SMA20	27.86%	Beta	1.69	Target Price	4.33
Payout	-	Debt/Eq	9.81	Sales Q/Q	-0.47%	SMA50	24.50%	Rel Volume	1.05	Prev Close	1.19
Employees	128	LT Debt/Eq	9.81	Earnings	May 11 BMO	SMA200	-3.89%	Avg Volume	1.90M	Price	1.21
IPO	Aug 26, 1987	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.00% 1.81%	Trades		Volume	2,009,255	Change	1.68%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-09-25	Initiated	H.C. Wainwright	Buy	$6
Jun-13-24	Initiated	Rodman & Renshaw	Buy	$7
Apr-23-24	Initiated	CapitalOne	Overweight	$6
Mar-13-24	Reiterated	Needham	Buy	$4 → $5
May-27-20	Initiated	Guggenheim	Buy	$24
Feb-20-20	Reiterated	Needham	Buy	$50 → $48
Jan-16-19	Reiterated	Needham	Buy	$66 → $64
Apr-05-18	Initiated	Evercore ISI	Outperform	$56
Mar-19-18	Reiterated	Mizuho	Buy	$28 → $35
Mar-01-18	Reiterated	Needham	Buy	$28 → $30
Jan-03-18	Initiated	Leerink Partners	Outperform	$22
Sep-27-17	Initiated	Northland Capital	Outperform	$40
Feb-27-17	Initiated	Needham	Buy	$28
Oct-26-16	Initiated	Aegis Capital	Buy
Sep-06-16	Resumed	Lake Street	Buy	$45
May-03-16	Initiated	Cantor Fitzgerald	Buy
Dec-10-15	Initiated	Lake Street	Buy	$45
Sep-23-15	Reiterated	Leerink Partners	Outperform	$38 → $57
Sep-02-15	Initiated	BofA/Merrill	Buy	$46
Aug-03-15	Reiterated	Brean Capital	Buy	$40 → $45

Show Previous Ratings

Apr-27-26 05:30PM	Heron Therapeutics to Report First Quarter 2026 Financial Results on Monday, May 11, 2026 (GlobeNewswire)
Feb-26-26 04:33PM	Heron Therapeutics, Inc. Q4 2025 Earnings Call Summary (Moby) +11.11%
04:09PM	Heron Therapeutics Inc (HRTX) Q4 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
03:48PM	Heron Therapeutics Q4 Earnings Call Highlights (MarketBeat)
12:30PM	Heron Therapeutics (HRTX) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
08:19AM	Loading…
08:19AM	Heron Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
08:00AM	Heron Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results (GlobeNewswire)
Feb-17-26 08:30AM	Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026 (GlobeNewswire)
Jan-10-26 09:35AM	Heron Therapeutics sees Q4 revenue $40.5M, consensus $39.83M (TipRanks)
Jan-09-26 09:29AM	Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF Largest Contributor to Q4 Growth (GlobeNewswire) +9.45%
Dec-04-25 08:15AM	Heron Therapeutics Announces Inclusion of APONVIE (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV) (GlobeNewswire)
Nov-04-25 04:06PM	Heron Therapeutics Inc (HRTX) Q3 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
09:30AM	Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
09:15AM	Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:13AM	Heron Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Loading…
08:00AM	Heron Therapeutics Announces Q3 2025 Financial Results and Highlights Commercial Progress (GlobeNewswire)
Oct-29-25 05:58PM	Heron Therapeutics Announces Appointment of Thomas Cusack to Board of Directors (GlobeNewswire)
Oct-21-25 04:20PM	Heron Therapeutics to Report Third Quarter 2025 Financial Results on Tuesday, November 4, 2025 (GlobeNewswire) -8.46%
Aug-15-25 07:45AM	Heron Therapeutics, Inc. Adopts Tax Benefits Preservation Plan to Protect NOL Assets and Shareholder Value (PR Newswire)
Aug-09-25 03:05AM	Heron Therapeutics Inc (HRTX) Q2 2025 Earnings Call Highlights: Strong Revenue Growth Amid ... (GuruFocus.com)
Aug-08-25 09:30AM	Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -28.26%
08:55AM	Heron Therapeutics (HRTX) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
07:52AM	Heron Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
07:45AM	Heron Therapeutics Announces Q2 2025 Financial Results and Highlights Commercial Progress (PR Newswire)
07:45AM	Heron Therapeutics Announces Comprehensive Capital Restructuring to Support Growth and Extend Maturity Profile (PR Newswire)
06:00AM	Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025 (PR Newswire)
Jul-28-25 09:42PM	Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025 (PR Newswire)
Jul-07-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Jul-04-25 08:50AM	These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
May-07-25 03:38PM	Heron Therapeutics: Q1 Paints A Potentially Rosy Picture For 2025 (Seeking Alpha) -6.61%
03:04AM	Loading…
03:04AM	Heron Therapeutics Inc (HRTX) Q1 2025 Earnings Call Highlights: Record EBITDA and Significant ... (GuruFocus.com)
May-06-25 09:30AM	Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics (Zacks) +13.62%
08:55AM	Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates (Zacks)
07:53AM	Heron Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
07:45AM	Heron Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
07:30AM	Heron Therapeutics Announces Settlement with Mylan Related to CINVANTI and APONVIE Patent Litigations (PR Newswire)
May-05-25 10:33AM	MTD Q1 Earnings Top Estimates, Sales Decline Y/Y, Shares Rise (Zacks) -7.79%
May-01-25 10:01AM	Akebia Therapeutics (AKBA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Apr-29-25 10:01AM	Heron Therapeutics (HRTX) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks)
Apr-28-25 06:55PM	Heron Therapeutics Announces Appointment of Mark Hensley as Chief Operating Officer (PR Newswire)
Apr-24-25 08:56AM	Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics (Zacks)
Apr-23-25 09:32AM	5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms (Zacks)
08:50AM	Why Investors Need to Take Advantage of These 2 Medical Stocks Now (Zacks)
Apr-22-25 04:05PM	Heron Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, May 6, 2025 (PR Newswire) +11.40%
10:15AM	Best Momentum Stocks to Buy for April 22nd (Zacks)
09:40AM	Are Medical Stocks Lagging Encompass Health (EHC) This Year? (Zacks)
07:24AM	New Strong Buy Stocks for April 22nd (Zacks)
Mar-26-25 03:57PM	Is Heron Therapeutics, Inc. (HRTX) The Hot Biotech Stock Under $5? (InsiderMonkey)
Feb-28-25 02:08AM	Heron Therapeutics Inc (HRTX) Q4 2024 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com) +20.49%
12:56AM	Q4 2024 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-27-25 09:30AM	Heron Therapeutics (HRTX) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) +19.88%
07:54AM	Heron Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
07:45AM	Heron Therapeutics Announces Fourth Quarter and Full-Year 2024 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Feb-13-25 04:20PM	Heron Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results On Thursday, February 27, 2025 (PR Newswire) +7.88%
Dec-23-24 04:05PM	Heron Therapeutics Announces Corporate Headquarters Relocation to Cary, North Carolina (PR Newswire)
Dec-03-24 04:36PM	U.S. District Court Upholds Validity of CINVANTI Patents (PR Newswire) +38.98%
Nov-13-24 02:05AM	Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights (GuruFocus.com) -5.47%
Nov-12-24 10:00AM	Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks) -30.43%
09:10AM	Heron Therapeutics (HRTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
08:06AM	Heron Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
07:55AM	Heron Therapeutics Announces Third Quarter 2024 Financial Results and Narrows Financial Guidance (PR Newswire)
Nov-07-24 09:15AM	Unveiling Heron Therapeutics (HRTX) Q3 Outlook: Wall Street Estimates for Key Metrics (Zacks)
Nov-04-24 05:00PM	Heron Therapeutics Announces Appointment of Michael Kaseta to Board of Directors (PR Newswire)
Oct-29-24 04:05PM	Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024 (PR Newswire) -7.33%
Oct-10-24 04:08PM	Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI, SUSTOL, and APONVIE as Alternatives During the Potential Shortage of Intravenous Fluids (PR Newswire)
Sep-25-24 08:00AM	Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire)
Sep-03-24 08:00AM	Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer (PR Newswire) -10.36%
Aug-06-24 07:30PM	Heron Therapeutics (HRTX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks) -25.09%
06:45PM	Heron Therapeutics (HRTX) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
05:36PM	Heron Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance (PR Newswire)
Jul-30-24 04:05PM	Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 (PR Newswire) +5.69%
Jul-15-24 08:00AM	Heron Therapeutics Announces the Inclusion of ZYNRELEF as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System (PR Newswire)
Jul-11-24 12:00PM	Heron Therapeutics (HRTX) Upgraded to Strong Buy: Here's What You Should Know (Zacks) +8.88%
Jul-02-24 08:00AM	Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire) -21.04%
May-29-24 08:05AM	Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF Vial Access Needle ('VAN') (PR Newswire)
May-21-24 12:00PM	What Makes Heron Therapeutics (HRTX) a Strong Momentum Stock: Buy Now? (Zacks)
May-08-24 12:30PM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q1 2024 Earnings Call Transcript (Insider Monkey)
03:10AM	Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Call Transcript Highlights: Significant ... (GuruFocus.com)
May-07-24 12:54PM	HRTX Stock Earnings: Heron Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
09:34AM	Heron Therapeutics Inc (HRTX) Q1 2024 Earnings Overview: Surpasses Revenue Estimates (GuruFocus.com)
09:30AM	Heron Therapeutics (HRTX) Reports Q1 Earnings: What Key Metrics Have to Say (Zacks)
09:05AM	Heron Therapeutics (HRTX) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
08:06AM	Heron Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Apr-30-24 10:01AM	Will Heron Therapeutics (HRTX) Report Negative Earnings Next Week? What You Should Know (Zacks) -7.20%
Apr-24-24 08:00AM	Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 (PR Newswire) -5.36%
Apr-11-24 04:05PM	Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City (PR Newswire) +7.69%
Mar-28-24 04:05PM	Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference (PR Newswire)
Mar-13-24 09:19AM	Heron Therapeutics, Inc. (NASDAQ:HRTX) Q4 2023 Earnings Call Transcript (Insider Monkey) +27.54%
07:04AM	Q4 2023 Heron Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-12-24 06:00PM	Compared to Estimates, Heron Therapeutics (HRTX) Q4 Earnings: A Look at Key Metrics (Zacks)
05:33PM	Heron Therapeutics Inc (HRTX) Exceeds Full-Year Revenue Guidance for 2023 (GuruFocus.com)
04:34PM	Heron Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates (PR Newswire)
Mar-07-24 09:15AM	Curious about Heron Therapeutics (HRTX) Q4 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
Feb-28-24 08:00AM	Heron Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results On Tuesday, March 12, 2024 (PR Newswire)
Feb-23-24 11:56AM	12 Best Rising Penny Stocks To Buy (Insider Monkey)
Feb-06-24 12:00PM	All You Need to Know About Heron Therapeutics (HRTX) Rating Upgrade to Strong Buy (Zacks)
Jan-25-24 06:44AM	Heron (HRTX) Gains 19% on FDA Nod for Zynrelef Label Expansion (Zacks)

Heron Therapeutics, Inc is a biotechnology company, which engages in the development of pharmaceutical products for acute care and oncology patients. Its product portfolio includes SUSTOL, CINVANTI, HTX-011 and HTX-034. The company was founded in February 1983 and is headquartered in Cary, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rubric Capital Management LP	10% Owner	Aug 08 '25	Buy	1.50	2,387,225	3,580,838	29,100,728	Aug 12 06:00 PM
Morgan Adam	Director	Aug 08 '25	Buy	1.50	1,766,546	2,649,819	8,753,290	Aug 12 05:02 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HRTX

Heron Therapeutics Inc

Upgrade your Finviz experience